Saturday, 14 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 14 December 2024
News

AstraZeneca patent under threat

Posted 28 November 2024 AM

Pharmacor is hoping to replicate its success in invalidating an extension of a Novartis patent with an AstraZeneca patent covering another heart drug.

In September AstraZeneca filed a claim in the Federal Court claiming Pharmacor was seeking to sell a generic of its heart drug Brilinta before the patent covering it expires on 31 May 2026, the result of being granted a patent extension.

To see the whole article, please login

Popular

Is 2024 the Year of Burnout?
Albo puts hand up for pharma selfie
Why pharma redundancies hurt
Top specialist in Deep Fake scam
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home